Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $108.3 million.

  • Aclaris Therapeutics' Shares Outstanding (Weighted Average) rose 51.84% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.3 million, marking a year-over-year increase of 51.84%. This contributed to the annual value of $71.4 million for FY2024, which is 0.84% up from last year.
  • Aclaris Therapeutics' Shares Outstanding (Weighted Average) amounted to $108.3 million in Q3 2025, which was up 0.05% from $108.3 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $108.3 million in Q3 2025 and a low of $51.8 million during Q1 2021.
  • Over the past 3 years, Aclaris Therapeutics' median Shares Outstanding (Weighted Average) value was $71.3 million (recorded in 2024), while the average stood at $80.8 million.
  • Data for Aclaris Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 52.16% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Shares Outstanding (Weighted Average) stood at $61.2 million in 2021, then increased by 8.91% to $66.7 million in 2022, then rose by 6.23% to $70.8 million in 2023, then increased by 0.84% to $71.4 million in 2024, then surged by 51.84% to $108.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $108.3 million for Q3 2025, versus $108.3 million for Q2 2025 and $107.9 million for Q1 2025.